Mylan’s adalimumab wins CHMP backing
A total of six biosimilar and generic medicines – three apiece – received positive opinions from the European Medicines Agency’s (EMA’s) committee for medicinal products for human use (CHMP) at its July 2018 meeting recommending the granting of marketing authorisations valid throughout the European Union (EU).
You may also be interested in...
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.